More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy

Nicole DeFeudis

Editor

Despite generics eating away at one of Bristol Myers Squibb’s highest sellers last year, Revlimid, CEO Giovanni Caforio maintained on Wednesday’s Q2 call that the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case

Exclusive: A small biotech will bring Roche's Angelman drug back to life

What's Pfizer's next move after shelving its oral obesity drug danuglipron?

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

More deals ahead for Bris­tol My­ers? CEO Gio­van­ni Caforio touts 'size ag­nos­tic' BD strat­e­gy

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy